News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis (Protocol I6T-MC-AMAN/LUCENT 1)

Study Status:

Closed for enrollment

Contact Information:

(956) 362-2394

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

Information: 

Principal Investigator
Sriramanchandra M. Badiga, MD
Co-PI
Edgar Lopez Pacheco
Sponsor
Eli Lilly and Company/USA
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram